By Plenary Sessions: Irja Lutsar

The speaker demonstrates deep expertise in the fields of medicine, pharmaceutical regulation, and virology, utilizing specific terminology (e.g., mRNA technology, peer-reviewed journals, validated laboratory tests). This expertise is supported by concrete data, such as the incidence rate of side effects (0.2–0.3% in Estonia) and the mention of the Nobel Prize being awarded to the developers of mRNA technology. The competence and impartiality of both the European Medicines Agency and the Estonian State Agency of Medicines are emphasized.

The speaker demonstrates knowledge of the international academic job market, referencing layoffs and the non-renewal of contracts at elite US universities, such as Harvard. Specific terminology is employed, including "knowledge-based state" and "doctoral studies." Furthermore, the speaker refers to information gathered via colleagues, indicating a profound grasp of the subject matter.